1)Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795-806, 2014
2)Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019:7247238, 2019
3)Kudo T, Arai K, Uchida K, et al. Very early-onset inflammatory bowel disease in Japan:A nationwide survey. J Gastroenterol Hepatol 36:151-155, 2021
4)Uhlig HH, Charbit-Henrion F, Kotlarz D, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease:a position paper from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 72:456-473, 2021
5)Pazmandi J, Kalinichenko A, Ardy RC, et al. Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol Rev 287:162-185, 2019
6)Nambu R, Warner N, Mulder DJ, et al. A systematic review of monogenic inflammatory bowel disease. Clin Gastroenterol Hepatol 20:e653-663, 2022
7)Umeno J, Hisamatsu T, Esaki M, et al. A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet 11:e1005581, 2015
8)Nakanishi T, Nakamura Y, Umeno J. Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action. Pharmacol Ther 223:107803, 2021
9)Ito N, Kudo T, Eguchi H, et al. Attenuated expression of SLCO2A1 caused by DNA methylation in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2023 doi:10.1093/ibd/izad116 [Epub ahead of print]
10)Rigaud S, Fondanèche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444:110-114, 2006
11)Yang X, Miyawaki T, Kanegane H. SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis. Pediatr Int 54:447-454, 2012
12)Ono S, Okano T, Hoshino A, et al. Hematopoietic stem cell transplantation for XIAP deficiency in Japan. J Clin Immunol 37:85-91, 2017
13)Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361:2033-2045, 2009
14)Xiao Y, Wang XQ, Yu Y, et al. Comprehensive mutation screening for 10 genes in Chinese patients suffering very early onset inflammatory bowel disease. World J Gastroenterol 22:5578-5588, 2016
15)Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease:implications for diagnosis and therapy. Gastroenterology 143:347-355, 2012
16)Qamar N, Fuleihan RL. The hyper IgM syndromes. Clin Rev Allergy Immunol 46:120-130, 2014
17)Ferrua F, Galimberti S, Courteille V, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency:Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. J Allergy Clin Immunol 143:2238-2253, 2019
18)Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 147:990-1007, 2014